Crinecerfont is named as an intervention in 3 current clinical trials in our USA and UK registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Neurocrine Biosciences (2). The most-studied condition is Congenital Adrenal Hyperplasia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
NCT07536269 · ClinicalTrials.gov ↗ · Congenital Adrenal Hyperplasia
|
Phase 2 | Recruiting | Neurocrine Switzerland GmbH | USA |
|
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915 · ClinicalTrials.gov ↗ · Congenital Adrenal Hyperplasia
|
Phase 3 | Active, closed | Neurocrine Biosciences | UK, USA |
|
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
NCT04806451 · ClinicalTrials.gov ↗ · Congenital Adrenal Hyperplasia
|
Phase 3 | Active, closed | Neurocrine Biosciences | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Lead sponsor | Trials |
|---|---|
| Neurocrine Biosciences | 2 |
| Neurocrine Switzerland GmbH | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
| Clinical trials in UK | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA and UK registers name Crinecerfont as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Neurocrine Biosciences (2) and Neurocrine Switzerland GmbH (1). The number in brackets is how many trials each organisation leads.
The registers we track list 1 entry for Crinecerfont: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Crinecerfont works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Crinecerfont works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Crinecerfont (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.